EMA Authorised: Constella (linaclotide) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

Constella (linaclotide) has been authorised by the EMA for its indication in irritable bowel syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Constella (linaclotide)

Snippet

Status: Authorised. Therapeutic area: Irritable Bowel Syndrome. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 19/06/2026